Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTO2 in relapsed or refractory multiple myeloma
NL-OMON47144Phase 2Active, not recruiting
- Sponsor
- Autolus Therapeutics plc
- Start
- Aug 2018
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AUTO2 in multiple myeloma (MM), sponsored by Autolus Therapeutics plc. Primary endpoints: Incidence of Grade 3 to 5 toxicity within the DLT period, Dose-limiting toxicity and persistence of AUTO2 and 2 more. Started Aug 2018; status: active, not recruiting.
02
Drugs
AUTO2
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON47144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47144.